Literature DB >> 1477321

Phosphate transport in brush border membranes from uremic rats. Response to phosphonoformic acid.

M Loghman-Adham1, M Szczepanska-Konkel, T P Dousa.   

Abstract

Phosphate retention in chronic renal failure may result in the development of secondary hyperparathyroidism and renal osteodystrophy. Thus, the addition of a specific phosphaturic agent may be beneficial in the treatment of chronic renal failure. Phosphonoformic acid (PFA), a specific and competitive inhibitor of Na(+)-Pi cotransport in renal and intestinal brush border membrane vesicles (BBMV), can induce phosphaturia in thyroparathyroidectomized (TPTX) rats. The aim of this study was to determine if PFA retains its inhibitory activity in uremic intestine and kidney. The effect of PFA, and its derivative phosphonoacetic acid (PAA), added in vitro, on Pi transport in BBMV prepared from the intestine and the remnant kidney of 5/6 nephrectomized (NX) rats was studied. In intestinal BBMV, the time course of Pi transport was not significantly different between NX and sham-operated (SH) control rats. Compared with SH, Na(+)-dependent Pi transport was reduced in BBMV from remnant kidney of NX, with no difference in Na(+)-independent or equilibrium uptakes. The reduced transport was specific for Pi with no change in Na+ gradient-dependent L-proline uptake, suggesting a normal Na+ conductance in uremic BBM. PFA and PAA produced a marked inhibition of Na(+)-Pi cotransport in intestinal and renal BBMV from NX and SH with similar relative inhibitory potency in uremic and control BBMV. It was concluded that the relative inhibitory potency of PFA or PAA on intestinal and renal Na(+)-Pi cotransport is preserved in uremia.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1477321     DOI: 10.1681/ASN.V361253

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  11 in total

1.  Kidney Disease Progression Does Not Decrease Intestinal Phosphorus Absorption in a Rat Model of Chronic Kidney Disease-Mineral Bone Disorder.

Authors:  Colby J Vorland; Annabel Biruete; Pamela J Lachcik; Shruthi Srinivasan; Neal X Chen; Sharon M Moe; Kathleen M Hill Gallant
Journal:  J Bone Miner Res       Date:  2019-11-15       Impact factor: 6.741

2.  Surface plasmon resonance (SPR) confirms that MEPE binds to PHEX via the MEPE-ASARM motif: a model for impaired mineralization in X-linked rickets (HYP).

Authors:  Peter S N Rowe; Ian R Garrett; Patricia M Schwarz; David L Carnes; Eileen M Lafer; Gregory R Mundy; Gloria E Gutierrez
Journal:  Bone       Date:  2004-11-24       Impact factor: 4.398

3.  ASARM peptides: PHEX-dependent and -independent regulation of serum phosphate.

Authors:  Valentin David; Aline Martin; Anne-Marie Hedge; Marc K Drezner; Peter S N Rowe
Journal:  Am J Physiol Renal Physiol       Date:  2010-12-22

4.  Pharmacological Npt2a Inhibition Causes Phosphaturia and Reduces Plasma Phosphate in Mice with Normal and Reduced Kidney Function.

Authors:  Linto Thomas; Jianxiang Xue; Sathish Kumar Murali; Robert A Fenton; Jessica A Dominguez Rieg; Timo Rieg
Journal:  J Am Soc Nephrol       Date:  2019-08-13       Impact factor: 10.121

Review 5.  Regulation of bone-renal mineral and energy metabolism: the PHEX, FGF23, DMP1, MEPE ASARM pathway.

Authors:  Peter S N Rowe
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2012       Impact factor: 1.807

6.  PF-06869206 is a selective inhibitor of renal Pi transport: evidence from in vitro and in vivo studies.

Authors:  Linto Thomas; Jianxiang Xue; Viktor N Tomilin; Oleh M Pochynyuk; Jessica A Dominguez Rieg; Timo Rieg
Journal:  Am J Physiol Renal Physiol       Date:  2020-08-03

7.  Expression of the Na/P(i)-cotransporter type IIb in Sf9 cells: functional characterization and purification.

Authors:  T Radanovic; H Murer; J Biber
Journal:  J Membr Biol       Date:  2003-07-15       Impact factor: 1.843

Review 8.  The wrickkened pathways of FGF23, MEPE and PHEX.

Authors:  Peter S N Rowe
Journal:  Crit Rev Oral Biol Med       Date:  2004-09-01

9.  Foscarnet alters antidiuretic hormone-mediated transport.

Authors:  B S Hoch; S J Shahmehdi; B M Louis; H I Lipner
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

10.  Gastrointestinal phosphate handling in CKD and its association with cardiovascular disease.

Authors:  Edward J Weinman; Paul D Light; Wadi N Suki
Journal:  Am J Kidney Dis       Date:  2013-06-12       Impact factor: 8.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.